HNF4A and GATA6 loss reveals therapeutically actionable subtypes in pancreatic cancer

- Brunton, Holly, Caligiuri, Giuseppina, Wright, Derek W., Paulus-Hock, Viola, Nixon, Colin, Thomson, Gemma, Jamieson, Nigel B., McGregor, Grant A., Evers, Lisa, McKay, Colin J., Gulati, Aditi, Cunningham, Richard, Upstill-Goddard, Rosie, Bailey, Ulla-Maja, Scarlett, Christopher J., Garner, Ian M., Nourse, Craig, Wong, Rachel, Dreyer, Stephan, Jones, Marc, Moran-Jones, Kim

Precision oncology in surgery: patient selection for operable pancreatic cancer

- Dreyer, Stephan B., Pinese, Mark, Jamieson, Nigel B., Scarlett, Christopher J., Colvin, Emily K., Pajic, Marina, Johns, Amber L., Humphris, Jeremy L., Wu, Jianmin, Cowley, Mark J., Chou, Angela, Nagrial, Adnan M., Chantrill, Lorraine, Chin, Venessa T., Jones, Marc D., Moran-Jones, Kim, Carter, Christopher Ross, Dickson, Euan J., Samra, Jaswinder S., Merrett, Neil D., Gill, Anthony J., Kench, JG, Duthie, F, Miller, DK, Cooke, S, Aust, D, Knösel, T, Rümmele, P, Grützmann, R, Pilarsky, C, Nguyen, NQ, Musgrove, EA, Bailey, PJ, McKay, CJ, Biankin, AV, Chang, DK, Australian Pancreatic Cancer Genome Initiative, Glasgow Precision Oncology Laboratory

Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer

- Moran-Jones, Kim, Gloss, Brian S., Spong, Suzanne M., Scarlett, Christopher J., Hacker, Neville F., Ghosh, Sue, Mok, Samuel C., Birrer, Michael J., Samimi, Goli, Murali, Rajmohan, Chang, David K., Colvin, Emily K., Jones, Marc D., Yuen, Samuel, Howell, Viive M., Brown, Laura M., Wong, Carol W.